WeVote
Log In

Bill

Bill

A 4163

Requires health insurers to provide coverage for biomarker precision medical testing.*

2024-2025 Regular Session Introduced by Bob Auth and 54 co-sponsors

New Jersey mandates health insurers cover biomarker precision medical tests to personalize treatment selection, effective April 2025.

Approved P.L.2025, c.49.
#healthinsur
0
WeVote Research Nonpartisan
Bill Summary · A 4163

Legislative bill overview

Bill A 4163 requires New Jersey health insurers to cover biomarker precision medical testing—diagnostic tests that analyze genetic, protein, and molecular markers to guide personalized treatment decisions. The bill passed both chambers unanimously and became law in April 2025, mandating insurers include these tests in standard coverage without imposing separate limitations compared to other diagnostic procedures.

Why is this important

Precision medicine testing can improve treatment outcomes by identifying which therapies will be most effective for individual patients, potentially reducing trial-and-error prescribing and associated costs. However, coverage mandates increase insurance premiums and administrative costs, which may be passed to consumers, and the tests themselves can be expensive and sometimes lack strong clinical evidence supporting their use in certain conditions.

Potential points of contention

  • Cost and premium impact: Mandatory coverage increases insurer costs, likely raising premiums for all policyholders, including those who never use these tests
  • Clinical evidence gaps: Not all biomarker tests have robust evidence of clinical utility; mandating coverage may fund tests with uncertain medical benefit
  • Scope ambiguity: The bill's definition of "biomarker precision medical testing" may be broad enough to capture emerging tests with unproven value, creating ongoing coverage disputes and implementation challenges

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.